Enzo-logo-750-500.jpg
Enzo Biochem Reports Second Quarter Fiscal 2021 Results; Company Provides Leadership and Corporate Updates
15. März 2021 16:05 ET | Enzo Biochem, Inc.
Total second quarter revenue of $31.5 million increased 62% year-over-year on continued recovery and expansion from impact of COVID-19 pandemicSecond quarter clinical laboratory revenue of $24.0...
Enzo-logo-750-500.jpg
Enzo Biochem to Participate in the H.C. Wainwright Global Life Sciences Conference
04. März 2021 08:00 ET | Enzo Biochem, Inc.
NEW YORK, NY, March 04, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that the Company will present...
Enzo-logo-750-500.jpg
Enzo Announces its GENFLEX™ Molecular Test Detects Current COVID-19 Variants
02. März 2021 08:00 ET | Enzo Biochem, Inc.
Results indicate that GENFLEX meets new FDA guidance calling for COVID-19 test developers to assess the impact of viral mutations on testing results Company also publishes new corporate white...
Enzo-logo-750-500.jpg
Enzo Biochem to Report Second Quarter 2021 Financial Results on Monday, March 15
01. März 2021 16:05 ET | Enzo Biochem, Inc.
NEW YORK, NY, March 01, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced today that it will report second...
Enzo-logo-750-500.jpg
Enzo Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin
03. Februar 2021 08:30 ET | Enzo Biochem, Inc.
NEW YORK, NY, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the recent issuance of U.S....
Enzo-logo-750-500.jpg
ENZO BIOCHEM’S BOARD OF DIRECTORS FORMS NEW CORPORATE DEVELOPMENT AND PLANNING & SUCCESSION COMMITTEES
20. Januar 2021 08:14 ET | Enzo Biochem, Inc.
NEW YORK, NY, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that the Enzo Board of...
Enzo-logo-750-500.jpg
ENZO BIOCHEM TO PARTICIPATE IN THE LIFESCI PARTNERS 10TH ANNUAL HEALTHCARE CORPORATE ACCESS EVENT
05. Januar 2021 08:00 ET | Enzo Biochem, Inc.
NEW YORK, NY, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, today announced that it will participate in...
Enzo-logo-750-500.jpg
ENZO BIOCHEM RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR TESTING POOLED SAMPLES ON THREE PLATFORMS INCLUDING COMPANY’S GENFLEX™ PROPRIETARY SYSTEM FOR DETECTION OF CORONAVIRUS SARS-CoV-2
04. Januar 2021 07:00 ET | Enzo Biochem, Inc.
- Use of pooled sampling with Enzo’s molecular diagnostic technology can help rapidly expand the number of people tested for COVID-19 - NEW YORK, NY, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzo...
Enzo-logo-750-500.jpg
ENZO RESPONDS AFTER REVIEWING THE POSITION OF INSTITUTIONAL SHAREHOLDER SERVICES
28. Dezember 2020 08:00 ET | Enzo Biochem, Inc.
NEW YORK, NY, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that it has reviewed the...
Enzo-logo-750-500.jpg
Enzo Biochem Hosting Key Opinion Leader Call on GENFLEX™ Molecular System for COVID-19 and the Role of Testing in a Post-Vaccine Treatment Environment
15. Dezember 2020 08:00 ET | Enzo Biochem, Inc.
Thursday, December 17th @ 12:00pmET New York, NY, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today announced that it will host...